Imprimis Pharmaceuticals said it is offering customizable compounded alternatives to Turing Pharmaceuticals’ high-priced Daraprim for as low as $99 for a 100-count bottle. Turing bought the U.S. rights to Daraprim in August and promptly increased the price of the drug from $13.50 per tablet to $750 per tablet, leading to backlash and headlines last month. Both Daraprim and Imprimis’ alternative are prescribed for infections afflicting patients with compromised immune systems, including patients with HIV/AIDS, pregnant women and children. The price hike raised questions about how prescription drugs can cost so much. Imprimis is also creating a new program, Imprimis Cares, that aims to provide these compounded formulations to combat high-priced generic drugs. Imprimis Pharmaceuticals is down 20.4% for the year so far. The Nasdaq is down 1.9% for the same period.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News